Suppr超能文献

肝肺综合征的新进展:全面综述

New updates on hepatopulmonary syndrome: A comprehensive review.

作者信息

Zaka Andrew Z, Mangoura Safwat A, Ahmed Marwa A

机构信息

Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt.

Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr, Cairo, 11829, Egypt.

出版信息

Respir Med. 2025 Jan;236:107911. doi: 10.1016/j.rmed.2024.107911. Epub 2024 Dec 9.

Abstract

Hepatopulmonary syndrome (HPS) is a serious pulmonary vascular complication that causes arterial hypoxemia in the setting of liver disease. HPS has a progressive course and is associated with a two-fold increased risk of mortality relative to cirrhotic patients without HPS. It primarily affects patients with portal hypertension. The key pathological features of HPS include intrapulmonary angiogenesis and vascular dilations (IPVDs). The prevalence of HPS varies widely due to inconsistent diagnostic criteria and a lack of standardized protocols. Despite advances in understanding its pathophysiology, no effective curative treatments for HPS exist. Liver transplantation remains the only definitive treatment, improving survival and altering the disease natural course. This review explores the pathophysiology, clinical features, and therapeutic strategies for HPS, highlighting recent advances in the literature.

摘要

肝肺综合征(HPS)是一种严重的肺血管并发症,在肝脏疾病背景下可导致动脉血氧不足。HPS呈进行性病程,与无HPS的肝硬化患者相比,死亡风险增加两倍。它主要影响门静脉高压患者。HPS的关键病理特征包括肺内血管生成和血管扩张(IPVDs)。由于诊断标准不一致和缺乏标准化方案,HPS的患病率差异很大。尽管在理解其病理生理学方面取得了进展,但目前尚无针对HPS的有效治愈性治疗方法。肝移植仍然是唯一的确定性治疗方法,可提高生存率并改变疾病的自然病程。本综述探讨了HPS的病理生理学、临床特征和治疗策略,重点介绍了文献中的最新进展。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验